Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.44 |
| ▸ | LPL | P06858 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18529899 | 0.85 | PDE4A (0.46) | ENPP2CA1CA2TAAR1HSD17B10 | |
| SCHEMBL24021238 | 0.84 | ENPP2 (0.42) | ENPP2LPLLIPGCA1CA2 | |
| SCHEMBL1024456 | 0.84 | ENPP2 (0.46) | ENPP2CA1CA2TAAR1HSD17B10 | |
| SCHEMBL18706356 | 0.82 | ALDH1A1 (0.54) | ENPP2CA1CA2MEN1ALDH1A1 | |
| SCHEMBL16293400 | 0.82 | ENPP2 (0.41) | ENPP2CA1CA2TAAR1 | |
| SCHEMBL16576656 | 0.81 | ENPP2 (0.43) | ENPP2CA1CA2TAAR1HSD17B10 | |
| SCHEMBL29954950 | 0.80 | HTR1A (0.42) | ENPP2CA1CA2ALDH1A1 | |
| SCHEMBL4652546 | 0.78 | ENPP2 (0.42) | ENPP2 | |
| SCHEMBL29953032 | 0.78 | ALDH1A1 (0.38) | ENPP2CA1CA2MEN1ALDH1A1 | |
| SCHEMBL3790779 | 0.78 | LPL (0.52) | ENPP2LPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2024-01-18 | — | — | US | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-2609089-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | ENPP2 2309/4885LPL 434/4885LIPG 600/4885 |
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | NLRP3, PYCARD, NOD1 | ENPP2 3092/4885LPL 1002/4885LIPG 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.